Histologically confirmed diagnosis of adenocarcinoma of the prostate
Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores ≤ 7
Clinical stage T1-2b (AJCC 7th edition)
PSA ≤ 10 ng/mL. PSA should not be obtained within 10 days after prostate biopsy.
ECOG Performance Status 0-1
You may not be if
Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years.
Evidence of distant metastases
Regional lymph node involvement
Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer. Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Previous hormonal therapy, such as LHRH agonists or LHRH antagonists, anti-androgens, estrogens, or surgical castration
Use of finasteride or dutasteride within 30 days prior to registration. PSA should not be obtained prior to 30 days after stopping finasteride or dutasteride.
Previous or concurrent cytotoxic chemotherapy for prostate cancer
Age \< 18
Patient unable to provide study-specific informed consent
Inability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
